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ABSTRACT
NONLINEAR STIFFNESS AND VISCOELASTICITY OF INHIBITOR-TREATED
BLOOD CLOTS BY TENSILE TESTING
by Wilson S. Eng
Although blood clots are vital to wound healing, little is known about what factors
influence clot stiffness and dynamic response. This work investigates the mechanics of
inhibitor-treated clots by direct tensile testing using a custom designed system for forces
below 1 N. Inhibitors that affect clot formation include blebbistatin, which affects myosin
II movement on actin, and cytochalasin D, which affects actin polymerization. The
hypothesis of this investigation is that blebbistatin will have a greater effect on
mechanical behavior than cytochalasin D, because the inhibition of myosin II will
weaken the overall clot more than actin. This hypothesis was investigated using clots that
were treated with blebbistatin and cytochalasin, using untreated whole blood as a
reference. Clots were tested from five different donors with at least two replicates from
each donor. Each clot was subjected to an initial stretch ratio of 1.5 to measure nonlinear
stiffness, followed by a series of 1 mm increments to record stress relaxation. At a stretch
ratio of 1.5, blebbistatin-treated clots exhibited 4.3% lower tensile stress than
cytochalasin-treated clots. The relaxation time constant for blebbistatin-treated clots was
10% faster than for cytochalasin-treated clots. This evidence supports the hypothesis
about the role of myosin II in blood and introduces experimental methodology that can be
extended to studies on mechanics of other soft biological tissues.
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1. INTRODUCTION
1.1 Background
Blood clots are critical to preventing incessant bleeding, thus saving lives. The
mechanical properties of the clot are vital to damming blood flow. The macroscopic
mechanical properties of a blood clot such as stress-strain response and yield strength are
functions of the blood composition and extent of cross-linking. Cross-linking is affected
by numerous factors, including levels of a coagulation enzyme known as factor XIII
(FXIII). However, several studies over the past few years have shown that blood clots are
mechanically and morphologically heterogeneous in microscale, and micromechanical
behavior can have important consequences in pathophysiological events such as stroke
[1].
Clots are biocomposite materials that are formed as liquid blood transforms into a
viscoelastic state. Fibrin, a key structural component of blood, is a polymer chain that has
been shown to shift from a random orientation to an aligned configuration when strained
[2]. The unique restructuring trait allows the clot to be flexible, but also resilient to
external forces [3]. However, mechanical testing of a clot is not a simple task. The fluidlike consistency of blood makes mechanical property testing with conventional
macroscale instruments such as an Instron® universal testing system (Illinois Tool Works,
Norwood Massachusetts, USA) difficult in terms of fixturing and small-force resolution.
Krasokha et al. found that casting blood into a mold was helpful in compressive testing
because of the known dimensions and cross-section [4]. However, even with a wellprescribed shape, the blood consistency is difficult for an experimental device to grasp,
1

requiring unconventional mounting techniques to contain the specimen within the
apparatus. In order to perform more informative mechanical testing of blood clots, there
is a need for a versatile and sensitive apparatus that can apply finely controlled
tensometric (i.e., force measurement under prescribed displacement) or extensometric
(i.e., displacement measurement under applied force) testing in a consistent way.
1.1.1 Blood Clotting Mechanics
Blood clots are complex and have many clotting factors and pathways that can create
a clot. Virchow’s triad, named after Rudolf Virchow, describes the three contributing
causes to thrombosis which are stasis, vessel wall injury, and hypercoagulability [5].
Fluid flow plays a role in the formation of clots. For example, a higher concentration of
platelets tends to occur in arterial clots, for which fluid flow tends to have a higher flow
rate than in veins [6]. The first stage of clotting occurs when there is an open wound.
Vasoconstriction of endothelial cells occurs, because of a lack of nitric oxide for
vasodilation during injury. In the second stage, platelets gather to form a plug at the
wound, but will not be cross-linked until after coagulation occurs to prevent further
bleeding with a stronger clot [7]. In the coagulation cascade there are two pathways,
known as the intrinsic pathway and extrinsic pathway. The intrinsic pathway is a slower
process using collagen and requires contributing roles of factors FXII, FXI, FIX, and FX.
The extrinsic pathway is a faster process requiring only FVII, tissue factor (TF), and FX.
The intrinsic pathway and extrinsic pathway meet at FX to start the common pathway.
The blood stream contains enzymes that change prothrombin (FII) into thrombin via
factor Xa (where the letter "a" indicates activator). Activated platelets are able to
2

rearrange their structure to attach to fibrinogen (FI) on neighboring platelets to create a
stronger plug at the injured site [8]. Eventually a network of platelets is created and its
strength is enhanced when thrombin converts the fibrinogen into a fibrin a mesh that
helps prevent blood flow. The fibrin network is then strengthened with the introduction of
FXIII, which cross-links the structure allowing for greater strain stiffening and
viscoelastic stiffness of blood clots [9].
This study will focus on the common pathway, for which collagen and tissue factor
are not involved with initiating the clotting process. Thrombin is the enzyme used to
initiate the clotting process, after which the clot will form and contract over time. Two
platelet components that provide hemostatic clot structure by working together are actin
filaments and myosin II motor proteins [10]. The platelet’s local actin-myosin
cytoskeleton relationship will be investigated further with the use of blebbistatin as a
known drug that inhibits myosin II [11] and cytochalasin D as a known drug that inhibits
actin polymerization [12]. Blebbistatin was found to change the biconcavity shape of red
blood cells (RBC) due to the inhibition of myosin II, indicating structural weakening
[13], whereas cytochalasin D was found to also weaken the clots by capping actin
filaments as shown through thromboelastography (TEG) which is a test for blood
coagulation efficiency [14].
1.1.2 Mechanical Properties of Blood
Many engineering materials such as metals exhibit linearly elastic mechanical
behavior that follow Hooke’s law, for which displacement is proportional to force.
However, blood clots behave differently, since the cross-linked fibrin network is strain
3

stiffening. The structural rearrangement of fibers results in tension that is not linearly
proportional to the applied displacement. Hyperelastic models, such as Neo-Hookean
model or Mooney-Rivlin model, are methods to describe the strain stiffening
characteristic.
There is also a difference when a clot is held at a prescribed displacement, because
stress relaxation will occur. Linearly elastic materials will exhibit a constant force when
extended and held at a fixed strain below the yield strain of the material. In the stress
relaxation of blood clots, however, tension decreases with time when the clot is held at a
fixed displacement. Viscoelastic models are used to describe this stress relaxation
phenomenon with the use of springs and dampers in various configurations. The most
basic models are the Maxwell model, consisting of a spring and damper in series, and the
Kelvin-Voigt model, consisting of a spring and damper in parallel. The Maxwell model is
better for stress relaxation for which displacement is fixed and the mechanical elements
encounter reduced force, and the Kelvin-Voigt model is better for creep for which force
is fixed and the mechanical elements undergo changes in geometry. The work in this
thesis will use the standard linear solid model, which is also known as a Zener or a
Maxwell representation that combines the Maxwell model and Kelvin-Voigt model [15].
1.2 Hypothesis
The work in this thesis investigates nonlinear stiffness and viscoelastic response of
blood clots by performing mechanical tensile testing of clots subjected to inhibitors. The
hypothesis is that blebbistatin affects stiffness and viscoelastic response of a clot more
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than cytochalasin D, because myosin II plays a larger role than actin in clot stiffness.
Inhibition of myosin II with blebbistatin is expected to create a weaker clot.
Myosin II protein is composed of two intertwined myosin chains which act along
actin filaments through an adenosine triphosphate (ATP) energy cycle. ATP binds to a
myosin II that begins to release the attached actin. The ATP is converted to adenosine
diphosphate (ADP), a phosphate and energy which winds the myosin like a spring to
provide mechanical energy. When the phosphate is released from myosin, the stored
energy from the myosin is released to move along the actin filament, thus contracting.
Blebbistatin can cause the myosin II to have low affinity to attach to actin, disrupting the
phosphate activation site, by binding to ATPase intermediate with ADP [16]. If the actin
filament is capped with cytochalasin D, then the contractions from the myosin will be
shorter. However, if there is no myosin II activity, then the membrane proteins will be
unable to contract and can be easily deformed [17].
1.3 Significance
There is still much unknown about the mechanical properties of blood clots.
Understanding the mechanical properties of blood clots is important because of the
potentially informative benefit to medical interventions such as drug therapy or
thrombectomy. Most prior work in mechanical characterization of blood clots has been
done using either rheometry, which measures tangential stress on a surface, or at the
nanoscale with atomic force microscopy (AFM), which focuses on individual clot
components. Direct tensile testing as applied in this thesis will provide an underinvestigated methodology for characterizing blood clot mechanics.
5

2. RELATED WORK
2.1 Mechanical Properties of Fibrin and Other Biomaterials
When fibrinogen and thrombin are combined, a fibrin polymer is formed. Fibrin is an
important structural component of blood clots that plays a role in treating ischemic
strokes and myocardial infarctions, but a balance is needed because too much fibrin can
lead to thrombosis and too little allows for uncontrollable bleeding [18]. Fibrin plays a
versatile role in wound healing and angiogenesis [19]. A specific use of fibrin is fibrin
sealant which is used in surgery as a hemostatic agent, preventing blood loss [20]. Fibrin
has viscoelastic properties which are important in understanding and treating thrombosis.
Fine clots are simpler to measure, because the planarity creates a two dimensional
interaction rather than a three dimensional interaction that is more complicated [21]. A
strong clot will deform differently than a weak one due to the nonuniform strain
stiffening network. Biological tissues and clots benefit from strain stiffening, which
allows for larger deformations prior to rupture [22]. A fibrin network can be cross-linked
with FXIII to create a stronger clot. Due to its versatility of strength and biocompatibility,
fibrin is already used in biomedical implants and tissue engineering [18].
Hydrogels are biomaterials consisting of water insoluble polymer chains with crosslinking properties [23]. Alginate is an example of a hydrogel material that exhibits
mechanical behavior similar to the mechanical behavior of fibrin. Sodium alginate, a
seaweed and kelp extract, has biocompatible characteristics that are favorable for wound
healing and drug delivery systems. Alginate increases angiogenesis which helps facilitate
the development of new blood cells increasingly for seven days [24]. Similar to fibrin,
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alginate can be cross-linked ionically, thermally, covalently, and through cellular
adhesion [25]. Drury et al. found that alginate ionically cross-linked with sodium chloride
had stress-strain curves with an initial concavity upward for the strain stiffening portions
of the plot [26]. When ionically cross-linked, alginate exhibits nonlinear stiffness similar
to blood clots. A few other hydrogels such as heparin, chitosan, and agarose are also used
in tissue engineering for their biocompatibility, biodegradability, and strain stiffening
mechanical characteristics [23].
2.2 Methods for Mechanical Testing of Soft Materials
Soft biomaterials are typically small and difficult to handle. The consistency is
similar to a gel, which can lead to slippage when trying to grasp mechanically. However,
certain measurement techniques alleviate this issue of slippage. The test methodologies
vary between apparatus types to bypass the specimen consistency. Rheometry uses the
specimen soft gel consistency to measure material properties. Chemical adhesion holds
the specimen in place and allows atomic force microscopy (AFM) to be used. A cast
specimen allows for compression or tension testing. Electrowetting uses an electric field
to manipulate the specimen into the desired configuration. The reviewed testing methods
provide guidance on developed techniques to overcome slippage from grasping soft
biomaterials.
2.2.1 Rheometry
A rheometer is a mechanical testing device that uses a rotating cone to compress the
specimen in a medium at a prescribed rotational speed, thus providing mechanical
characterization based on shear rate. Kim et al. studied fibrin, collagen, and fibrin7

collagen with a rheometer that compressed the specimens to 1/10 of the initial thickness
to gather shear modulus information [27]. The shear elastic modulus G’ and shear loss
modulus G” are the typical properties that are reported from rheometry measurements.
Wen et al. [22] found that an out of phase viscous response of G’’is less than G’ in crosslinked hydrogels, because nonlinear elasticity has a nonlinear stress and strain
relationship. Polyacrylamide (PA) gels, for example, have G’ increase with larger strains,
indicating that strain stiffening is occurring. G’ and G” are proportional to the stored
elastic energy and the energy dissipated [28].
Ayala et al. studied the effects of cytochalasin D and blebbistatin on blood with
rheometry [29]. A dosage dependency between 2.5 µM to 5.0 µM cytochalasin D and 5.0
µM to 10 µM blebbistatin was found, because the shear modulus continued to change
[29]. If the shear modulus was steady, then the entire clot structure was inhibited.
Tutwiler et al. tested whole blood by keeping the clot size at a constant volume with the
rheometer and found that the increase in red blood cells weakens the clot contractile
stress [30]. Rheometry methods proved to be useful in studying blood clots and inhibitor
effects, but would not be able to measure actual tensile forces acting on soft biological
materials.
2.2.2 Atomic Force Microscopy
In nanoscale, Markert et al. used AFM to test several biomaterials including alginate,
collagen, and fibrin [31]. With AFM devices, a measured force can manipulate the
specimen and image simultaneously. Studies by Feller showed that an AFM probe tip can
adhere to blood and provide nanonewton force measurements with micron-scale
8

displacements by partially submerging the cantilever beam [32]. The nanometer scale
allows for studying the mechanical properties of single components of a clot. Other
methodologies can prepare the specimen for AFM such as electrospinning, which allows
for a thinner fiber to be created [33]. However, larger networks in the macro scale are
difficult to understand, because of the very fine resolution of AFM devices.
Examining a whole clot at macroscale, Lam et al. investigated the mechanics and
dynamics of platelets with force measurements [34]. Crow et al. further introduced
cytochalasin D and blebbistatin to understand the inhibitors effects on clot retraction [35].
When treated with a cytochalasin D concentration of 500 nM, clots contracted at 0.40
µm/min. When treated with a blebbistatin concentration of 30 µM, clots contracted at
0.24 µm/min. Clot contraction ceased while using 1 µM cytochalasin and 50 µM
blebbistatin concentrations [35].
2.2.3 Compression Testing
Compression testing is another test methodology performed on biomaterials.
Typically the test specimen will be in a holder and compressed to obtain relevant
mechanical properties. This system benefits from the not having to grasp onto the soft
biomaterial. Krasoskha et al. tested porcine blood by compression at 0.25 mm/s by a plate
in a chamber where the clot takes the chamber shape [4]. Beyond 70% compression a
strain stiffening effect was observed with a large increase in stress [4]. However, the
methodology did not have a specified predetermined clot shape and chamber walls could
have affected the results. There was no indication of a retraction period for the clot, such
that the observations could have been more related to plasma rather than the actual clot.
9

In contrast with Murphy et al. who performed compression testing on round fibrin gel
specimens between two plates on an Instron® universal testing machine [36]. The
compression of the fibrin gel did not have any interference, because the gel was able to
retain its own structure. The compression testing proved to be a simple way of testing
clots, but tensile testing is more indicative of clots breaking apart in embolisms.
2.2.4 Tensile Testing
Flexures have been used to measure contraction and small movements in tensile
testing. Known flexural stiffness allows for simple forces measurements with a known
displacement. Polydimethylsiloxane (PDMS) strain sensing beams were used to measure
clotting contraction forces with the Young’s modulus of the flexure and displacement
[37]. The same principles were used for flexures to study the strength of an onion skin in
dry and wet conditions [38]. A similar experiment by Kim et al. [39] was done using a
piezoelectric actuator and a flexure as the known force, a variation of the approach by
Zamil et al. [38]. The flexure stiffness was known, allowing the onion movement to be
measured.
Currently, there is no current standard for tensile testing soft biological materials
such as hydrogels and fibrin. There are commercial products that can test soft biological
tissue, such as the DMT wire myograph (Danish Myo Technology, Aarhus, Denmark).
However, the device is specialized for loop arteries that attach to the two wires and are
pulled apart. ADMET has a BioTense Bioreactor (ADMET, Norwood Massachusetts,
USA) that measure forces between 1 mN to 5 N at 1.2 mm/s, but does not have a quick
clamping system for soft biological materials. Other industrial testers such as an Instron®
10

universal testing machine can be used, but a large specimen must be made to obtain
readings. Thrombin added to fibrinogen and cross-linked with FXIII were used in a
casting of 4 mm diameter x 60 mm long, and the measured forces were as high as 0.8 N
with an extension of two times the normal length [2]. Soft biological materials may not
always be large, so a smaller specimen scale solution is necessary.
Some tensile testers are created for very specific tests. Jacquet et al. created an
extensometer to test the mechanical properties of skin on human subjects [40]. The
device used a linear variable displacement transducer (LVDT) and strain gauges to
measure skin displacement. Krone et al. bonded a hydrogel to silicon, allowing clamps to
directly hold the composite specimen to be pulled apart with a Futek load cell [41].
Krasokha et al. casted porcine blood in an aluminum mold, and then aged the clots for 48
hours to be pulled apart horizontally with their tensile tester [4]. However, the data drawn
from the tensile testing did not comprise of a continuous data set and had two distinct
different linear slopes in the stress vs. elongation plots. A contributing factor may have
been that aged clots were more brittle. Tensile testing proved to be possible on blood
clots, but the data were not as refined as other methods such as AFM or rheometry,
possibly due to the difficulty of pulling on blood clots.
2.2.5 Electrowetting-On-Dielectric
Electrowetting-on-dielectric (EWOD) is a principle in digital microfluidic devices
that uses electrostatic forces to move a liquid on a specialized hydrophobic platform. The
platform has a set of activation pads that turn a voltage on and off to move the fluid
around the device [42], [43]. EWOD platforms can be used to test clots, since the device
11

can activate separate pads to pull the specimen apart or move to the desired location. The
device is has fine enough resolution to create 900 nL cross-linked alginate specimen on
the platform [44]. The placement of calcium chloride relative to the sodium alginate is
important, because irregular shaped gels can be formed due to the cross-linking reaction
time. A uniform gel was created by moving the calcium to the alginate, so the excess
liquid could easily be removed after gel formation [44]. The EWOD platform is
promising as an emerging technology, but the blood viscosity and clot strength may be
difficult to overcome.
2.3 Specimen Holding Methods
Holding methods vary from apparatus to apparatus as indicated earlier. The main
methodologies are through compression, clamping, and special adhesion coatings.
Rheometry does not require special holding methods, because the volume is controlled by
the rotating compression disk. Krashoka et al. relied on the chamber dimensions and plate
to keep the specimen in place [4]. Murphy et al. was able to cast samples into a
prescribed shape when platens were used to compress the specimen [36].
A variety of methods and test shapes have been used for tensile testing. Typically all
of the hardware used for holding clots or clot-like specimens are simplistic flat clamps
with screws to adjust the clamping force. The clamping methodology is possible if the
specimen is large and structurally strong enough to withstand outside forces. Brown et al.
created a specimen that was 4 mm diameter cylinder x 60 mm long cast of fibrinogen,
thrombin, and FXIII mixture [2]. The specimen retained its shape and was held together
with a rubber clamp for tensile testing. Krone et al. had a different approach by using a
12

thin film bonded with a hydrogel, using a bonded bi-layer to characterize the mechanical
response via strain energy functions [41]. The method factored out the contributing
mechanical role of silicon to obtain the mechanical properties of only the hydrogel.
Chemical adhesion techniques have also been used to secure a specimen on to glass
slides for pull testing. In order to promote adhesion of fibrin to glass substrates, surfaces
were pretreated with fibrinogen as in [45]. Fibrin can also attach to glass sides via poly-llysine (PLL) coating mixed with fibrinogen, which has a net negative charge at pH 7.4
allowing for a bond based on polarity [46]. Adhikari et al. used a peripheral venous
catheter tube to create fibrin specimens in 0.8 mm x 5 cm which were able to retain the
shape even after being removed with a syringe to be placed on glass slides using
cyanoacrylate adhesive [18]. A collagen adhesion method uses collagen directly on
slides, allowing time for gelling to promote adhesion [47]. Alginate can adhere to slides
with PLL and then barium chloride, under which conditions the PLL, will bind to the
prostate-specific membrane antigen on one side and alginate will adhere to the other side
[47].
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3. THEORY
Three applications of mechanical engineering theory are presented in this chapter: (1)
stiffness compensation for inline sensing, (2) nonlinear material stiffness, and (3) lumped
parameter modeling of viscoelasticity.
3.1 Stiffness Compensation for Sensing
The ability of a cantilever-type load cell to measure small forces is partially attributed
to the load cell’s relatively large compliance (compared to a button or s-beam load cell,
for example). Placing the load cell in series is advantageous because the load cell cannot
be overloaded. Once the specimen tears, the actuator is no longer coupled to the load cell.
As the actuator applies displacement, however, the mechanical response of the system
as measured by the load cell includes a mechanical response of the test specimen as well
as the stiffness of the load cell body. Figure 1 illustrates the mechanical coupling
arrangement.

Figure 1. Mechanical coupling from actuator through specimen to load cell, as arranged
spatially (a) and as equivalent stiffness elements (b).
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Thus, in order to isolate specimen mechanics, both the displacement and the stiffness
contributions must be decoupled. The elongation δs of the specimen is the displacement
δtotal of the actuator minus the tip deflection δL of the load cell. The tip deflection of the
load cell can be measured in real time under a microscope or characterized prior to
experimentation based on the measured stiffness kL (i.e., by applying a known load,
measuring tip deflection, and fitting a line to the slope). The stiffness of the load cell can
also be estimated by a cantilever beam equation using Young's modulus (if known) and
geometric dimensions, although measurement using known weights is more direct and
accurate.
When considering only the instantaneous stiffness of the specimen (i.e., not
including viscous effects), the load cell stiffness kL and the specimen stiffness ks have an
equivalent stiffness keq as shown in equation (1).

(1)
In quasi-static tensile testing, the force F throughout the series assembly is constant,
and the ratio of measured force to actuator total displacement provides the equivalent
stiffness, such that the measured force and applied displacement are related to specimen
stiffness as shown in equation (2).

(2)
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Rearranging equation (2) provides an expression for the specimen stiffness in terms
of the measured force, applied displacement, and (separately characterized) load cell
stiffness, as shown in equation (3).
(3)

3.2 Nonlinear Material Stiffness
Broad categories of material models include linear elastic, nonlinear elastic
(hyperelastic, for example), and viscoelastic, all of which can be characterized by
uniaxial testing. For mechanical testing, linear elastic materials are conventionally
characterized solely by tensile or compressive Young's modulus E. Poisson's ratio ν is
also an important linear elastic parameter, but for small test specimens the value is not
typically measured and reported.
Three common ways of describing geometric change for uniaxial tensile test
specimens are elongation δ, axial strain ε, and stretch ratio λ. Elongation δ, of a loaded
specimen is defined as difference between the specimen length L (in its loaded state) and
its original length Lo. Axial strain ε is the component of displacement gradient along the
axial direction, and for discrete measurements can be expressed as the ratio of elongation
to original length. Stretch ratio λ is commonly used in strain energy functions for
hyperelastic material models, and is defined as the ratio of the specimen length L when
loaded and its original length Lo when not subject to a load. In this study, Cauchy stress,
also known as true stress, will be reported in this thesis. Cauchy stress differs from
engineering stress (which assumes a constant area) by accounting for the change in the
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specimen cross-sectional area throughout the pull testing. Cauchy stress is more
completely described as a tensor σ, but for uniaxial tension only the normal component
σ11 along the direction of stretch is considered (for which the "11" subscript will
subsequently be omitted).
A convenient way to evaluate the strain stiffening properties of the blood clot is with
a hyperelastic model. Even though blood is a biological material, blood still exhibits
elastic qualities because the material will retract when released after extension. Although
complex materials are strain-rate dependent, many soft tissues are known to be
"pseudoelastic" (i.e., relatively independent of strain rate) [48] and strain-rate sensitivity
is not examined in this thesis. There are several hyperelastic material models that have
been investigated for soft tissue biomechanics. Neo-Hookean and Mooney-Rivlin models
are typically used to describe rubbers, but blood clots have similar elastic deformation
properties [49], [50]. Constitutive models are based on strain energy density functions,
for which a set of constitutive parameters are typically fit to experimental data under
specified loading conditions (e.g., uniaxial, biaxial, or shear) in order to quantify material
behavior [51]. Equation 4 will be used as a two-parameter Mooney-Rivlin model [50] to
create a responsive fit for blood clots in this study, and the hyperelastic parameters C1
and C2 will be extracted from experimental data. However, the Mooney-Rivlin model
will not have an accurate viscoelastic model with only uniaxial testing, because pure
shear and equibiaxial testing are needed for a complete viscoelastic model [52].
(4)
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3.3 Lumped Parameter Modeling of Viscoelasticity
Connective tissues have been shown to exhibit both linear elastic and viscoelastic
behavior under tension [53]. The Maxwell model is comprised of one spring and one
damper in series and is useful for describing stress relaxation under a prescribed
displacement. The Kelvin-Voigt model is comprised of one spring and one damper in
parallel, and is useful for describing creep under a prescribed load. A three-parameter
viscoelastic model commonly known as a "standard linear model" (occasionally referred
to as a Kelvin body [54] or a Zener model [15]) uses a spring and damper in series
arranged in parallel with another spring. This model captures both stress relaxation and
creep phenomena that the Maxwell and Kelvin-Voigt model represent independently. An
expanded version of the standard linear model is known as the generalized Maxwell
model, which is a standard linear model in parallel with many Maxwell models which
allows for more control in the model. van Kempen performed a rheological test on clots
with different platelet concentrations contracting on fibrin networks and used a modified
generalized Maxwell approximation to extract time-dependent, nonlinear viscoelastic
properties to verify against other rheological approaches [55]. Schmitt et al. characterized
animal blood by utilizing several models – Maxwell, Kelvin-Voigt, Jeffrey, Zener, and
generalized Maxwell. The most appealing of the models is the Zener model, which is
comprised of both the Maxwell and Kelvin-Voigt models, by being able to predict stress
relaxation along with creep. Schmitt et al. found that more parameters, such as the
generalized Maxwell, did not guarantee a better fit when characterizing blood clot
dynamics [15].
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The lumped parameter used in this thesis is shown in Figure 2, consisting of a threeparameter model with two springs and one damper, assembled in series with an additional
spring element to account for stiffness of the load cell. This configuration was chosen
because the load cell displacement is not trivial and would contribute to smaller k1, k2,
and η parameters by approximately 10%. Compensation for the load cell stiffness thus
provides a more accurate representation of specimen stiffness.

Figure 2. Lumped parameter model, with k2 as a spring in parallel to spring k1, and
damper η in series added to loadcell kL.
The differential equation for the standard linear model (without kL in Figure 2) is
shown in equation 5, where F is time-varying force and δs is the elongation of the tested
specimen.
(5)
In the case of stress relaxation, the imposed elongation remains constant such that its time
derivative is zero for time t > 0. Substituting a time constant τ = η/k1 leads to the
differential equation in a single variable F(t).
(6)
The Laplace transform with parameter s results in equation 7.
(7)
19

Solving this differential equation with initial condition of F(0) = k1δs+ k2δs results in
equation 8 as the solution for elongation in the specimen as a function of time.

(8)
The force is then decoupled on the left in equation 9 to perform an inverse Laplace
transform.
(9)
After the inverse Laplace transform, equation 10 presents the force-time relationship for
the standard linear model without the load cell.
(10)
Adding a load cell in series with the standard linear model results in equation 11, where
the total observed displacement δtotal accounts for elongation of the specimen as well as
deflection of the cantilever load cell. Larger forces and a faster displacement will be seen
in the stress relaxation portion of the experiment, thus the load cell spring stiffness is
included in the equation.
(11)
Equation 11 will be the equation used to fit a curve to the experimental data.
MATLAB (The MathWorks, Inc., Natick, Massachusetts, USA) has a nonlinear least
squares fit function that uses the three variable inputs k1, k2, and η. The function
minimizes the residual errors between the data sets and requires an initial guess. Both of
the MATLAB Newton step-based solvers "trust-region reflective" and "Levenberg-
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Marquardt", yielded the same C1 and C2 parameter values in the Mooney-Rivlin equation
seen in equation 4.
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4. METHODOLOGY
4.1 Device Design
The apparatus for tensile testing consists of a motorized nanopositioner (MP-285,
Sutter Instrument, Novato, CA), a full-bridge thin cantilever load cell (LCL Series,
OMEGA Engineering, Norwalk, CT), and a data acquisition (DAQ) signal conditioner
DI-1000U (Loadstar Sensors, Fremont, CA). The specimen is placed between the
actuator and load cell using magnetic clamps, as shown in Figure 3.

Figure 3. Major component of tensometer system.
The nanopositioner has 25 mm range with fine resolution of 40 nm per step. Speeds
are selectable from 20 µm/s to 2.9 mm/s. The data reported in this paper was recorded
using the 113 g capacity load cell from the LCL product series, but load cells are
interchangeable with higher-load products of the same family (e.g., 227 g, 454 g, 816 g).
The DI-1000U DAQ has 24-bit resolution (over 16 million levels) and up to 80 Hz
sampling rate.
The test specimen is mechanically in series with the load cell, offering a fail-safe
design such that the specimen would always tear before the actuator can deflect the load
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cell beyond its designed range of operation. However, this series arrangement requires
that the tip deflection of the load cell be subtracted from the raw displacement of the
actuator, in order to determine the net elongation of the test specimen.
4.1.1 Functional Requirements
Mechanical properties of biomaterials are difficult to characterize experimentally
because many relevant biomaterials such as hydrogel, collagen, and fibrin are pliable and
viscoelastic. Furthermore, test specimens for substances such as blood clots tend to be
small in size (i.e., on the order of a few millimeters), requiring fine-resolution positioning
(i.e., submicron) and sensitive force measurement. Mechanobiological studies further
require high frequency data recording (i.e., faster than 10 Hz), preferably under
simultaneous microscope imaging, in order to monitor events such as structural
remodeling or localized rupture while strain is being applied. A low-profile tensile tester
that applies prescribed displacement up to several millimeters and measures forces with
resolution on the order of millinewtons has been designed and tested.
4.1.2 Specimen Clamping Method
Clamping has been the most successful methodology for pulling soft biomaterial test
specimens with tensile testing. An aluminum clamp with a toothed crevice as seen in
Figure 4 allows for two points of contact to hold the test specimen. A magnet was press
fitted inside the clamp bottom to create a clamping force with the top clamp that has a
steel screw attached. The magnetic clamping force can be readjusted by turning the screw
to the desired height and locking the screw in place with the appropriate nut. An
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adjustable force allows for the clamps to compensate for different sized specimens and
unwanted damage to the specimens.

Figure 4. Adjustable magnetic clamps used to hold the specimen.
4.1.3 Displacement Measurement
The load cell was calibrated using three known weights of 10.950 g, 20.947 g, and
51.248 g, as measured by a precision balance (Sartorius Research, Gottingen, Germany).
By adjusting the mN/mV calibration factor, the calibration error was limited to 1% for
loads up to 508 mN. The rated capacity of the load cell was 1.1 N, which is well above
the specimens maximum tested force of 300 mN.
Stiffness of the load cell was determined by applying known weights and measuring
the corresponding cantilever displacement with an optical comparator (HB400, Starrett,
Athol, MA). The comparator has a resolution of 2.5 µm at 10X magnification. The load
cell was placed horizontally in the comparator and a clamp was used to hold the base
stationary. Calibration weights of 10.950 g, 20.947 g, and 51.248 g were applied and the
corresponding tip deflection was measured using the optical comparator. As shown by
the force vs. displacement data in Figure 5, the cantilever load cell had a stiffness of kL =
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96.883 N/m. The corresponding R² value of 0.9985 with respect to straight-line fit
indicates a highly linear behavior of the cantilever.

Figure 5. Cantilever load cell stiffness.
Figure 6 shows a representative plot of the zero-load offset and noise of the load cell.
The signal standard deviation over a 300 s period was 48 µN. The plot shows a mean
offset of 50 µN and a root mean square (RMS) variation of 68 µN. Typical specimen
tests are on the order of 100 mN, such that the signal-to-noise ratio is very high. These
measurements are consistent with manufacturer rating of ± 0.02% accuracy.

Figure 6. Zero-load offset and noise for the load cell.
Zero-load return behavior of the load cell was inspected by repeatedly applying and
releasing manual load up to 200 mN by pushing with a mechanical micromanipulator.
The load cell returned to zero (within the previously determined mean offset of 50 µN)
after each cycle, as evidenced in Figure 7.
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Figure 7. Zero-load return upon applying and releasing manual loading cycles.
4.2 Experimentation
4.2.1 Experimental Design
Test were conducted at room temperature. The blood draw was compliant with the
approved F16134 San Jose States Institutional Review Board (IRB) protocol. Five
different donors were used for the test. Calcium is removed during the blood draw to
prevent unwanted clotting from initiating and is accordingly reintroduced before pull
tests to restore the blood to its more natural composition. Four different treatments were
tested with whole blood as the control, blebbistatin for the myosin II inhibitor,
cytochalasin D for the actin inhibitor, and the combination of blebbistatin plus
cytochalasin for observation of combined effect.
The human blood specimens were fabricated and tested within a 4 hour period after
the blood was drawn for each treatment. Four specimens were made in each well on a
chamber slide (Nunc Lab-Tek, Thermo Scientific, Waltham, MA). The tests were
conducted with two or three successful pulls for each treatment. The order of testing and
fabrication was whole blood, blebbistatin, blebbistatin plus cytochalasin, and then
cytochalasin. Between each treatment there was a 30 minute time window to test each set
of four specimens to complete all of the testing within 4 hours of the blood draw. The
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whole blood was created first, the blebbistatin incubation mix was started immediately
after, the blebbistatin plus cytochalasin mix started 30 minutes after the blebbistatin, and
finally the cytochalasin incubation was started 30 minutes after the blebbistatin plus
cytochalasin mix to perform all of the test within the 4 hour time period.
The actuator was set to move at a prescribed rate of 100 µm/s for 3 mm and then 400
µm/s for 1 mm subsequent increments with approximately 30 s of relaxation between
each increment until a set distance of 6 mm was reached. A mechanical dial indicator was
attached to an adjustable mount to verify the distance traveled by the actuator and to
corroborate the digitally displayed on the MP-285 actuator.
4.2.2 Specimen Fabrication
The dispensing of the blood was performed under a biological safety hood (SG303,
The Baker Company, Sanford ME). 500 µL specimens were cast into a chamber slide
with dimensions of 11 mm x 19.5 mm x 11.25 mm to obtain a consistent rectangular
starting shape. The estimated starting size of all clots prior to retraction was 11 mm x
19.5 mm x 2.3 mm. All blood clots were given 1.5 hours to retract and to stabilize in a
relaxed state such that contraction forces would not interfere with results. The retraction
of each specimen varied and thus required a microscope and a side camera to measure the
specimen to calculate the actual dimensions, because inconsistent image analysis can
adversely affect the results of the study [56].
The whole blood control treatment consisted of 0.3 U of thrombin (Thermo Fisher
Scientific, Waltham, MA) to initiate the clot, 10 µM of calcium chloride (Thermo Fisher
Scientific, Waltham, MA) to replace the calcium initially removed during blood draw,
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and 600 µL of blood to mix everything together. After mixing the clot three times
(moving the fluid up and down) in the pipette for 5 s, 500 µL of the blood mixture was
dispensed into the specimen well and the clot was allowed to retract and stabilize for 1.5
hours in the biological safety hood.
The other three treatments blebbistatin (Thermo Fisher Scientific, Waltham, MA),
blebbistatin plus cytochalasin mix, and cytochalasin (Thermo Fisher Scientific, Waltham,
MA) were incubated at room temperature (23 °C) for 30 minutes on a lab rocker (VariMix Platform Rocker, Thermo Fisher Scientific, Waltham, MA) at approximately 2 Hz
with eppendorf tube secured horizontally to improve mixing with the whole blood. Table
1 shows the concentrations used for the experiment. The blebbistatin and cytochalasin
concentration values were higher than in other reported studies [35] to prevent
contraction of the clot, by completely inhibiting the desired mechanism. The blebbistatin
treatment had 300 µM of blebbistatin mixed with 600 µL of blood, the cytochalasin
treatment had 10 µM of cytochalasin mixed with 600 µL of blood, and the combined
blebbistatin plus cytochalasin had 300 µM of blebbistatin, 10 µM cytochalasin, and 600
µL of blood. All three treatments had 0.3 U of thrombin and 20 µM of calcium added
after the incubation period and were mixed within approximately 5 s in a pipette three
times prior to dispensing 500 µL of the treated blood into the specimen wells. All
specimens were left in the biological safety hood for 1.5 hours to complete retraction.
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Table 1. Composition and timing used for each specimen type

4.2.3 Apparatus and Measurement System
The nanopositioner started at its left-most position to utilize the entire travel of the
motor. The clamps were placed on the actuator and the load cell mount. The load cell and
its corresponding clamp were attached on a micromanipulator (Cascade Microtech,
Beaverton, OR), initially set flush with the opposing clamp on the actuator. Another
micromanipulator with a dial indicator was set to zero prior on the load cell
micromanipulator. The load cell clamp was then moved away from the actuator clamp
until 4.24 mm on the dial indicator is read for total of 6 mm initial working distance (each
clamp has a channel width of 0.88 mm). The dial indicator was moved perpendicular to
the actuator and zeroed to verify the distances the actuator moved.
The test data were extracted in terms of force and converted to the respective true
stress vs. stretch ratio curves and stress relaxation curves. A specimen was continuously
pulled to 3 mm at 100 µm/s which was 50% of the initial 6 mm working length to obtain
the true stress vs. stretch ratio data. The specimen was allowed to rest for 30 s between
each increment. All subsequent increments added additional 1 mm extend-and-hold
operations, moving at 400 µm/s. At the end of the test, a total specimen length of 12 mm
was reached at 100% specimen elongation.
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The load cell was zeroed without the bottom support to neglect the weight of the
specimen in the initial pull. Prior to pulling, the microscope was set to capture top-view
images of the specimen to extract top cross-sectional dimensions, and the side camera
was used to side-view images to extract thickness. The microscope captured three images
during the pull, each 8 s apart. The force recording from the data acquisition software
(LoadVUE, Loadstar Sensors, Fremont, CA) and actuation of the nanopositioner were
started simultaneously and force measurements were recorded at 30 Hz. The actuator was
controlled by legacy software "mp285.exe" provided by the nanopositioner manufacturer
(Sutter Instrument Company, Novato, CA), and followed the sequence stated earlier. As
soon as the first actuation stage completed, the second specimen side view picture was
taken prior to the 30 second timer starting for the stress relaxation pulls. The pull timing
allowed for 3 s of travel. After, every 30 s the next actuation stage was enabled. The
times were 30 s, 1 minute 3 s, 1 minute 36 s, 2 minutes 9 s, and 2 minutes 42 s. The entire
pull portion of the experiment took 3 minutes 12 s to complete.
4.2.4 Image Analysis
The image analysis tool Fiji was used to measure the three top-view images for the
width w and two side images for thickness t [57]. Figure 8 show a typical set of images
that were captured during the true stress vs. stretch ratio portion of the experiment from
the top view. Each image was used to understand the changing cross-section of the
specimen. The 12.7 mm clamp width was a reference feature used to measure the clot
width at the center of the specimen in each image. A fitted line from each of the three
images was used to estimate the change in width and thereby to determine the cross30

sectional area of the specimen. Force measured by the load cell was divided by crosssectional area to calculate true stress.

Figure 8. Standard top down three images at 8 s apart for each specimen.
Figure 9 shows the two images taken on the side to measure the change in thickness
over time for the true stress vs. stretch ratio portion of the experiment. The 3 mm clamp
thickness was used as a reference feature to calculate the for clot thickness at the center
of the specimen. A straight line drawn across the center was used to measure the
specimen thickness change. The specimen cross-section was not quite rectangular, but
closer to an elliptical profile with rounded edges. Equation 12 used the width and
thickness founded to calculate the true stress with the changing area as an ellipse.
(12)
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Figure 9. Side view of specimen being pulled from initial (left) to 3 mm extension (right).
4.2.5 Data Analysis
Figure 10 shows a representative example of raw data plot from the test. The first
portion of data was used to plot true stress vs. stretch ratio. The first stress relaxation
curve (in the 30 s to 60 s time frame) following the initial pull was discarded so that each
step change for stress relaxation could be applied in a consistent manner. The next three
pulls was used for the stress relaxation portion of the study.
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Figure 10. Representative extension curve to extract true stress vs. stretch ratio plots and
stress relaxation plots.
The force for the strain stiffening portion of the test reached a maximum of 3.5 g
which was a factor of 10 less than the load cell operating range of up to 113 g. Force was
divided by the changing area to provide the true stress of the specimen. The time output
was converted to a stretch ratio with the known displacement rate and initial specimen
length. Mooney-Rivlin fit parameters can be extracted from the plots.
The first three seconds of each relaxation curve was analyzed by fitting the
experimental data to equation 11. Figure 11 shows a sample plot of the three pull
distances overlaid with the fitted equation 11 used to extract parameters k1, k2, and η. The
important parameter k1 and η make up the time constant τ = η/k1, because k2 only shifts
the height of the plot and does not play a role in how fast the curve decreases.
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Figure 11. A consolidated fitted curve plot at the 4 mm, 5 mm, and 6 mm on the first 3 s
of the specimen pulls.
To determine donor-to-donor variability the Mooney-Rivlin parameters was used in a
one way analysis of variance (ANOVA) at a 99% confidence interval (α = .01) based on
whole blood specimens only. C1 and C2 each had an independent ANOVA performed,
because the values are dependent on each other. Each parameter will need to have a high
p-value for all the donors to be equal. The differences between the maximum and
minimum C1 and C2 values within each donor provides the within donor variability
information.
4.3 Sources of Uncertainty
In the test calibration, a 10.950 g weight displayed an average force output of 108.54
mN resulting in a 1.05% error from the theoretical force 107.42 mN, the 20.95 g weight
displayed an average force output of 207.29 mN resulting in 0.86% error from the
theoretical force 205.52 mN, and 51.250 g weight measured 508.16 mN, resulting in a
1.07% error from the theoretical force 502.76 mN. The scale used to measure the weights
had a resolution of 0.1 mg.
Actuator speeds were verified against the program values. The speed was checked
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against the distance. A 12.7 mm depth gauge was attached on the actuator to verify
distance traveled for the two prescribed rates of 20 µm/s and 60 µm/s. The actuator was
programmed to move 2.54 mm at the rates of 20 µm/s and 60 µm/s, and a stopwatch
verified the times to be 127 s and 42.3 s, respectfully. The dial has a resolution of 25.4
µm and the estimated average human reaction time is roughly 0.25 s.
The stiffness of the load cell calculation will vary on many parameters, because all of
the measurements will affect the length and cross-sectional values used to determine the
stiffness value. The length, width, and thickness were measured with a micrometer with a
resolution of 2.5 µm. The load cell deflection was measured on an optical comparator by
putting the load cell flat lengthwise to allow for known weights to be added at the end. A
zero reference was created with the unloaded load cell. Weights were added the static
system and then measured by a comparator with an uncertainty of ± 2.5 µm. In the image
analysis there was a pixel uncertainty of approximately ± 10 µm. Table 2 is a
summarized list of uncertainties that was used to calculate apparatus uncertainties in true
stress reporting and load cell stiffness.
Table 2. List of uncertainties

Using the list of uncertainties in Table 2, the apparatus measurement uncertainty was
calculated. Applying equation 13, the propagation of uncertainty, a square root sum of
squares of uncertainties, is used to estimate the total uncertainty. A combined error u, is
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characterized by f which is the function with the unknown uncertainty with the sources of
error. The first source of uncertainty is 𝑦1 with an uncertainty range defined as 𝑢1 .
(13)
To find the cross-sectional area uncertainty from the image analysis equation 14 is used.
The two sources of uncertainty are thickness and width which are both from image
analysis tool. All specimens have different cross-sections and a smaller cross-section
would result in a larger stress uncertainty in later calculations. The assumed dimensions
are 0.85 mm thick x 7.74 mm wide, because those were the smallest measured values for
each of their respective features. The combined uncertainties resulted in a cross-sectional
uncertainty of 0.06 mm² with the image analysis tool.
(14)
With the result from equation 14, the reported stress uncertainty is calculated with
equation 15. By using the load cell uncertainty from Table 2 and the previous area
uncertainty an overall stress uncertainty was calculated. The upper range specimen force
of 34.3 mN and lower range specimen area of 5.18 mm² is used to calculate a stress
uncertainty of 102.63 Pa or 1.55% error for the nonlinear stiffness calculations.
(15)
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For equation 16, the load cell stiffness uncertainty, an assumed force of 106.4 mN from
the calibration measurement and a deflection of 1.24 mm. An uncertainty of 0.17 N/m
was found for the load cell stiffness.
(16)
The apparatus loading style is subjected to sine error due to the vertical orientation of
the load cell and the horizontal pulling of the specimen in relation to the load cell.
Equation 17 is used to calculate the sine error ε. The clamp distance h from the load cell
is 24 mm to the specimen contact and the angle θ was calculated from force deflection
with the load cell stiffness. The maximum forces used are 34.3 mN for the nonlinear
stiffness and 106.4 mN for the stress relaxation resulting in an error of 0.42 mm and 1.30
mm respectively.
(17)
However, with image analysis, the clamp shift was found to be closer to 0.12 mm at the
34.3 mN pull. The loading of the cantilever was not exactly the same as the specimen
being pulled on the clamps, because the mounting adapter could not attach to the weights
used for calibration.
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5. RESULTS AND DISCUSSION
There are two main types of results from a single pull sequence. The first result is
how the inhibitor treatments affect the stiffness of the specimen, as revealed in a plot of
true stress vs. stretch ratio. The second result is how the inhibitor treatments affect the
stress relaxation of the specimen.
5.1 Effective Nonlinear Stiffness of Blood
Figure 12 shows fitted two-parameter Mooney-Rivlin curves for true stress vs. stretch
ratio for each of the treatments, averaged across all donors and specimens. The plot
shows that whole blood has the highest stiffness of all the treatments, as expected
because the structure has not been altered with any inhibitors. Based off of the maximum
true stress found on the plot in Figure 12, cytochalasin decreased clot stiffness by 33.7%
and blebbistatin decreased clot stiffness by 37.9%. The blebbistatin plus cytochalasin mix
decreased the clot stiffness by 44.8%. The difference between blebbistatin and
cytochalasin is 4.3%, and is greater than the 1.55% uncertainty in true stress, as estimated
in Section 4.3.
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Figure 12. Fitted Mooney-Rivlin hyperelastic model on the averaged treatment results
across all donors.
The true stress vs. stretch ratio showed that the whole blood clot was structurally
stiffer than the inhibitor-treated clots. Blebbistatin has a lower true stress at maximum
stretch ratio than cytochalasin by 4.3%. Although based on limited sample size and fixed
concentration, this offers some supports to the hypothesis that blebbistatin affects the
blood structure to a greater extent, by preventing the cross-linking of actin filaments
through the inhibition of myosin II, thus reducing the overall clot contraction strength.
Cytochalasin affects the actin filament length by preventing actin from depolymerization
and repolymerization, shortening the myosin II travel distance on the actin. However, the
capped actin filaments did not inhibit the myosin II function, causing the cytochalasin
treatments to yield stiffer clots. Blebbistatin prevented myosin II function, which created
a gap between the actin proteins, because there were no protein cross-linkage
interactions. The larger distances between proteins during the pull testing, resulted in a
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weaker clot structure, because there was empty space that could easily collapse. The
blebbistatin plus cytochalasin combination affected two different mechanisms, which are
the myosin II travel on actin filaments and the actin filament polymerization length. The
combination of both inhibitors resulted in clots with the lowest overall stiffness.
5.2 Viscoelastic Response of Blood
The bar graph in Figure 13 shows how the time constant τ differs for the four
different types of blood clots. A smaller value of τ means rapid decay and implies relative
inability to sustain tensile stress. As seen in Figure 13, the fastest τ was observed for the
blebbistatin treatment, and whole blood had the slowest time constant at 4 mm extension.
At 5 mm extension, the blebbistatin treatment also exhibited the fastest time constant but
the cytochalasin treatment showed slower response than whole blood. At 6 mm, the
inhibitor mix blebbistatin plus cytochalasin was faster than blebbistatin and cytochalasin
was the slowest. The overall data across the three distances imply that blebbistatin, with
the fastest time constant, weakens the clot more than cytochalasin. The cytochalasin
specimen decay time became slower than whole blood at larger pull distances, which was
unexpected.
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Figure 13. Time constant τ values for each treatment at 4 mm, 5 mm, and 6 mm.
All of the treatments have a similar unexpected trend with slower time constants at 5
mm, but a slightly faster time constant at 6 mm as seen in Table 3. At larger distances,
environmental factors such as prolonged air exposure can dry-out the clot and alter the
results. Thus, behavior at 6 mm extension is less revealing about changes in clot
structure. The time constants at 4 mm extension are considered more accurate, since there
are fewer uncontrollable variables in the first pull than in the later pulls. The faster time
constants from the stress relaxation exhibit the treatment effects. Blebbistatin has a 10.2%
faster time constant than whole blood. The cytochalasin specimen did not differ from
whole blood greatly by only being 0.0317% lower.
Table 3. Time constant differences between inhibitor treatments and the whole blood
control at each extension distance
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5.3 Donor Variability
5.3.1 Within-Donor Variability
The variability within donors is shown in Figure 14. Figures 14-1 and 14-2 show
specimens in black that are initially weaker than the rest, but see strain stiffening, causing
the specimen to reach a higher end stress. The increased strain stiffening resulted in
specimen curve in black to intersecting with other specimen curves. Figures 14-2, 14-3,
and 14-4 all have a within donor maximum stress difference of 2 kPa at the 1.45 stretch
ratio.
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Figure 14. Plots of whole blood donor replicate variability for five donors where each
curve is a separate test specimen.
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The ranges of fitted Mooney-Rivlin parameters C1 and C2 are presented in Table 4,
arranged by donor. Donor 2 had the highest variability among the specimens in terms of
plot shape, as shown in Figure 14-2, with the largest overall calculated variation of 58%
for C1 and of 62% for C2. The larger C2 range compared to the C1 range correlated with
curves intersecting. Each parameter affects the curve, such that C1 values change the true
stress maximum height and C2 values change the plot curvature shape. Donor 1, 3, and 4
had comparable ranges, but Donor 5 had the smallest difference between values.
Table 4. Whole blood Mooney-Rivlin hyperelastic parameters C1 and C2 range for each
donor

5.3.2 Donor-to-Donor Variability
The variability of all treatments across donors was unpredictable with no obvious
trend as seen in Figure 15. The whole blood with no treatment across all donors had the
highest variability. In Donor 5 the whole blood specimen with highest observed stiffness
had maximum true stress that was approximately twice the true stress of the next highest
whole blood specimen. The effects of all other treatments were difficult to determine,
because they varied between donors. In Donor 1, blebbistatin and cytochalasin are shown
with comparable stiffnesses. In Donor 2, cytochalasin appeared to have no effect on the
blood. In Donor 3, the results are similar to the averaged Mooney-Rivlin results with
whole blood as the stiffest specimen and blebbistatin weaker than cytochalasin. In Donor
4, blebbistatin is the weakest, but in Donor 5 blebbistatin is unexpectedly higher than
cytochalasin.
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Figure 15. Plots of true stress vs. stretch ratio averaged across five donors per treatment
response by each donor.
Analysis of variance (ANOVA) was used to check for statistically significant
differences among donors, with each of the two Mooney-Rivlin parameters as separate
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response variables, and donor number as the factor of interest. The control whole blood
was chosen to determine if there were any difference between the donors and to avoid
inhibitor effects on specific donors. Table 5 shows that the C1 value for five donors had
weak evidence of any differences with a p-value of 0.60. Donor 2 showed the highest
variance and donor 5 had the lowest variance, similar to the within donor range shown in
Figure 14.
Table 5. Mooney-Rivlin parameter C1 one way ANOVA comparison across donors for
whole blood

In Table 6, C2 has a p-value of 0.71, showing weak evidence that the donors are
unequal. The high p-value indicates that all the curvatures were similar. Donor 2 showed
the highest variance and Donor 5 had the lowest variance which was also shown in
Figure 14 whole blood donor plots.
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Table 6. Mooney-Rivlin parameter C2 one way ANOVA comparison across donors for
whole blood

The ANOVA of the Mooney-Rivlin parameters showed no statistically significant
differences with respect to donor for whole blood specimens. Thus the averages from
each donor are used for comparing each of inhibitor treatments, even though the
composition of specimens from each donor may have had a different platelet and red
blood cell count.
The average maximum stress between donors for all treatments for a stretch ratio of
1.45 is shown in Table 7. Whole blood was used as the reference and for each donor there
was a shift in the effectiveness of blebbistatin and cytochalasin observed in the plots. In
Table 7, whole blood, blebbistatin, and cytochalasin had a donor maximum stress range
of 2.23 kPa, 0.29 kPa, and 1.26 kPa respectively. The percentage difference from whole
blood ranged from 24.5% to 55.4% for blebbistatin and 6.81% to 69.8% for cytochalasin.
The donor-to-donor variability for drug effectiveness had a large range in percentage
change.
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Table 7. Average maximum stress value percent difference at 1.45 stretch ratio for each
treatment with whole blood as the reference

The time constants also varied from donor-to-donor shown in Table 8. For all donors
except Donor 3, the treatment time constants at 4 mm were slower than whole blood time
constant. In all donors, at 4 mm, the blebbistatin treatment time constants were faster than
the cytochalasin treatment time constants. Whole blood, blebbistatin, and cytochalasin
had a time constant range between donors of 0.22 s, 0.25 s, and 0.21 s respectively. The
time constant ranges varied by no more than 24% within any given treatment type.
Table 8. Average τ value percent difference at 4 mm with whole blood as the
reference

5.3.3 Other Sources of Uncertainty
Within the specimen fabrication, there were small air bubbles (on the order of 100 µm
in diameter) on the specimen when being pulled as seen in Figure 16. The bubbles would
sometimes appear over time during the test, even though bubbles were not visible in the
original specimens prior to testing. The largest bubbles typically measure approximately
0.3 mm in diameter. Overall, the bubbles are sparse and a single clot may have as many
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as 10 on the surface of the clot ranging from 0.18 mm to 0.30 mm in diameter. None of
the bubbles ruptured or created tears in the clot.

Figure 16. Top view image of bubbles present in the clot pull.
Figure 17 shows that the clot spills over the clamp when being secured in the
apparatus. Small force components can be attributed to the blood surface tension with the
clamp as a wetted meniscus. All of the clots behaved this way with plasma leaking out of
the sides, but it is difficult to quantify the adhesion affected clot strength. The current
assumption is that the plasma adhesion force is the same for all specimen tests. The test
was not performed under controlled temperature or humidity, and the lack of controlled
environment may have allowed the clot to dry and shrink over time.

49

Figure 17. Side image of blood adhering to the clamp creating a wetted meniscus.
The extent and uniformity of mixing are difficult to verify, because different volumes
were used to obtain the desired treatment concentration. The assumption is that all
samples are evenly mixed, meaning the thrombin, calcium chloride, and inhibitors were
equal throughout the clot. There is a possibility that nonuniform mixing for blebbistatin
was more pronounced, because the blebbistatin clot uses a larger volume of 53 µL to mix
for a final concentration of 300 µM, whereas cytochalasin uses a volume 12 µL to mix
for a final concentration of 10 µM.
The 300 µM blebbistatin and 10 µM cytochalasin are assumed to inhibit all myosin II
and actin respectively. Since there is only one dosage performed for each treatment, the
effects are possibly dose dependent [29], [58]. There is an uncertainty if the dosages were
used at a toxic level and potentially causing adverse effects on the blood clot. From
similar literature, Tutwiler et al. used 200 µM blebbistatin in their studies of clot
contraction [9]. Ayala et al. used 5 µM of cytochalasin D and 10 µM of blebbistatin and
found that in rheometry the results were the opposite, by showing that cytochalasin
affected the clot more with only 5 µM concentration [29]. However, Crow et al. used 500
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nM of cytochalasin and 30 µM blebbistatin to conclude that blebbistatin affected the clot
contraction more at those concentrations [35]. In this same research by Crow, 1 µM
cytochalasin and 50 µM blebbistatin concentrations were found to inhibit all contraction
in the clot.
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6. CONCLUSIONS
6.1 Addressing the Hypothesis
The hypothesis asserted that blebbistatin affects the stiffness and viscoelastic
response of blood clots more than cytochalasin D, because myosin II plays a larger role
than actin in affecting the mechanical strength of the clot. The variability of nonlinear
stiffness for each individual donor was substantial, for example the C1 parameter which
affects the maximum true stress, had a variation as large as 61% for whole blood.
However, the nonlinear stiffness in terms of true stress vs. stretch ratio averaged across
five donors showed that blebbistatin affected the clot maximum true stress at 1.5 stretch
ratio by 4.3% more than cytochalasin. The 4.3% difference is greater than the calculated
1.6% uncertainty associated with quantifying true stress. From the averaged viscoelastic
parameters at each increment of elongation, blebbistatin decayed more rapidly than
cytochalasin, with a 10% shorter time constant at 4 mm elongation. Both the nonlinear
stiffness and stress relaxation revealed similar results, which were consistent with
biophysical reasoning that the myosin II inhibition prevents the cross-linking of the actin
and myosin travel on actin, thus influencing structural behavior to a greater extent than
cytochalasin.
Differences between the inhibitor-treated specimens were detectable with a tensile
testing methodology. There was no statistically significant difference (α = 0.01) found
across five different donors. The time constant for cytochalasin was slower than the time
constant for whole blood by 3.5% at 5 mm and 6.9% at 6 mm.
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6.2 Recommendations for Future Work
Based on this work, a climate controlled environment is recommended to minimize
possible environmental effects on the specimen during testing. A different actuator can be
used, because the apparatus only needs a few millimeters of travel. Greater consistency
can be achieved by using a programmable actuator that could pull and allow for 30 s of
stress relaxation, instead of manually timing the pull start and stop sequence. An
integrated system to activate the actuator, initiate data acquisition, take the side-view
images, and the top view images could reduce possible errors introduced by operator. The
clamps can be improved by developing a way to achieve constant prescribed force
(magnetic or otherwise). A shorter initial working length will prevent unwanted specimen
sag on clamps to start at a proper length for more consistent results. In the stress
relaxation analysis, the viscoelastic model in this thesis uses force over time, which does
not account for overly large clots to cause a slower stress relaxation time constant. A
stress over time standard linear model may provide different results, because the area can
be normalize to provide a more precise comparison between treatments [59]. The tensile
testing approach with clamps allows for a more in depth understanding of clots and other
soft biological materials in the micromechanical scale.
A minimum threshold is needed to understand when the drugs will interact with the
clot. The established threshold will allow for a controlled change in parameters to avoid
studying unwanted treatment effects not related to the desired mechanism. After
minimum drug concentrations have been established, a two factor, three level factorial
design of experiments can be conducted. The three levels would be low, medium, and
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high doses of each treatment to check for the required threshold to inhibit all activity or
extrema, and to also reveal possibly nonlinear interactions.
A different approach to supplement the testing is to use Western blotting [60] to
corroborate and verify the effects of both drugs. The test can have the same four
treatments of whole blood, blebbistatin, cytochalasin D, and the blebbistatin plus
cytochalasin. The protein markers can be made to view the myosin II and the actin II for
each treatment and compare gels for each treatment. If the gel is more pronounced then
there is an indication of a higher concentration. A visual representation can be obtained
by staining the platelets to highlight the actin and myosin II proteins.
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APPENDIX A: APPARATUS TECHNICAL DOCUMENTS
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APPENDIX B: GLOSSARY
Alginate - An extract from brown seaweed cell walls that can be mixed with calcium and
sodium salts to create a flexible fibre.
Actin - A thin protein in the cytoskeleton that interacts with myosin II in a primitive
sarcomere like.
Aneurysm - A localized region in a blood vessel that is abnormally large due to
thrombosis or embolization which is a piece of material inside the blood vessel causing
blockage.
Blebbistatin - A myosin inhibitor for myosin II which would prevent ATP, resulting in a
low energy state.
Coagulation - The process of blood changing from a liquid to a solid with the activation
of platelets and fibrin to form a clot. Thrombosis or hemorrhaging can occur due to
coagulation clotting issues.
Collagen - A main structural protein that can be found throughout the body.
Clot - Solidified blood.
Cytochalasin - A fungal mobilite that can block and inhibit polymerization and
elongation of actin.
Cytochalasin D - Inhibits actin polymerization by capping the ends of the actin chain.
Denaturation - A process where proteins can lose structure, typically caused by the
environment such as heat or a chemical reaction.
Eptifibatide - An antiplatelet drug that prevents blood from clotting and be used for heart
attacks in people with severe chest pains.
Factor XIII (FXIII) - Also known as fibrin stabilizing factor, is an enzyme that will
cross-link fibrin.
Fibrin - A fibrous protein formed from thrombin and fibrinogen. The protein can be
polymerized with platelets to form a clot over a wound.
Fibrinogen - Also known as factor I and when combined with thrombin it forms a fibrin
based blood clot.
Fibrinolysis - Prevents blood clots from growing too large and becoming problematic.
The fibrin clot is broken down and the remains are cleared by proteases or by organs like
the kidney or liver.
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Fibroblasts - Synthesizes extracellular matrix and collagen, which is critical to wound
healing.
FFP (Fresh Frozen Plasma) - Liquid portion of whole blood that can be used to treat
conditions with low blood clotting factors.
Hemarthrosis - Bleeding in the joints due to lack of factor XIII.
Hemophilia - The ability to have blood clot is severely reduced relative to normal
population due to missing clotting factors.
Hemostatic- An antihemorrhagic agent that contracts tissue to seal wounds.
Hydrogel - A gel with water as the main liquid, can be used in biological functions to
help with wound healing.
Ischemic - Restricted blood flow to regions causing a lack of oxygen needed for basic
cellular metabolism.
Lysis - Breaking down.
Myocardial infarction - Another term for heart attack which happens when there is
restricted blood flow to the heart, causing damage to the heart.
Myosin II - A protein that assists in providing cellular structure by binding and traveling
along actin filaments.
Plasma - Contributes to 55% of the body’s total blood volume which contains dissolved
proteins such as fibrinogen. Also contains proteins, ions, nutrients, and waste.
Platelet - Also known as thrombocytes and is a component of blood that can clump and
clot blood.
PRP (Platelet Rich Plasma) - A concentration from whole blood. Platelet-rich plasma is
centrifuged to remove red blood cells. Has a greater concentration of cellular growth
factors (e.g. PDGF, IGF-1, EGF, and TGF-beta) activating fibroblasts.
PPP (Platelet Poor Plasma) - Blood plasma with a low number of platelets that can have
an elevated level of fibrinogen.
Stroke - Restricted blood flow due to ischemia or hemorrhage where there is bleeding in
the skull.
Thrombin - Acts as a serine protease that converts soluble fibrinogen into insoluble
strands of fibrin.
Thrombosis - Formation of a blood clot in a blood vessel with platelets and fibrin.
Thrombolysis - Breakdown of a blood clot in a blood vessel.
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APPENDIX C: EXPERIMENTAL PLOTS

Mooney-Rivlin 𝐶1 and 𝐶2 parameters in dot Extracted viscoelastic 𝑘2 spring parameter
plot form
at 3 second

Extracted viscoelastic 𝑘1 spring parameter
at 3 s

Extracted viscoelastic η spring parameter at
3s
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Extracted viscoelastic 𝑘1 spring parameter
at 30 s

Extracted viscoelastic 𝑘2 spring parameter
at 30 s

Extracted viscoelastic η spring parameter at
30 s
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APPENDIX D: RAW EXPERIMENTAL IMAGES

Donor 1 whole blood top view images

Donor 1 blebbistatin top-view images

Donor 1 cytochalasin top-view images

Donor 1 blebbistatin plus cytochalasin
mixture top-view images
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Donor 2 whole blood top-view images

Donor 2 blebbistatin top-view images

Donor 2 cytochalasin top-view images

Donor 2 blebbistatin plus cytochalasin
mixture top-view images
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Donor 3 whole blood top-view images

Donor 3 blebbistatin top-view images

Donor 3 cytochalasin top-view images

Donor 3 blebbistatin plus cytochalasin
mixture top-view images
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Donor 4 whole blood top-view images

Donor 4 blebbistatin top-view images

Donor 4 cytochalasin top-view images

Donor 4 blebbistatin plus cytochalasin
mixture top-view images
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Donor 5 whole blood top-view images

Donor 5 blebbistatin top-view images

Donor 5 cytochalasin top-view images

Donor 5 blebbistatin plus cytochalasin
mixture top-view images
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Donor 1 whole blood side-view images

Donor 1 cytochalasin side-view images

Donor 2 whole blood side-view images

Donor 2 cytochalasin side-view images

Donor 1 blebbistatin side-view images

Donor 1 blebbistatin plus cytochalasin
mixture side-view images

Donor 2 blebbistatin side-view images

Donor 2 blebbistatin plus cytochalasin
mixture side-view images
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Donor 3 whole blood side-view images

Donor 3 blebbistatin side-view images

Donor 3 cytochalasin side-view images

Donor 3 blebbistatin plus cytochalasin
mixture side-view images

Donor 4 whole blood side-view images

Donor 4 blebbistatin side-view images

Donor 4 cytochalasin side-view images

Donor 4 blebbistatin plus cytochalasin
mixture side-view images
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Donor 5 whole blood side-view images

Donor 5 blebbistatin side-view images

Donor 5 cytochalasin side-view images

Donor 5 blebbistatin plus cytochalasin
mixture side-view images
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